Search Results - "Beach, Charles L."

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial by Gore, Steven D, Fenaux, Pierre, Santini, Valeria, Bennett, John M, Silverman, Lewis R, Seymour, John F, Hellström-Lindberg, Eva, Swern, Arlene S, Beach, Charles L, List, Alan F

“…The phase III AZA-001 study established that azacitidine significantly improves overall survival compared with conventional care regimens (hazard ratio 0.58…”
Get full text

Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine by Santini, Valeria, Fenaux, Pierre, Mufti, Ghulam J., Hellström-Lindberg, Eva, Silverman, Lewis R., List, Alan, Gore, Steven D., Seymour, John F., Backstrom, Jay, Beach, Charles L.

“…Objective:  Myelodysplastic syndrome (MDS) treatment can initially worsen patients’ clinical condition and they may discontinue therapy before achieving…”
Get full text

Prolonged survival with improved tolerability in higher‐risk myelodysplastic syndromes: azacitidine compared with low dose ara‐C by Fenaux, Pierre, Gattermann, Norbert, Seymour, John F., Hellström‐Lindberg, Eva, Mufti, Ghulam J., Duehrsen, Ulrich, Gore, Steven D., Ramos, Fernando, Beyne‐Rauzy, Odile, List, Alan, McKenzie, David, Backstrom, Jay, Beach, Charles L.

“…Summary In the phase III AZA‐001 trial, low‐dose cytarabine (LDara‐C), the most widely used low‐dose chemotherapy in patients with higher‐risk myelodysplastic…”
Get full text

A Phase I Study in Patients with Solid or Hematologic Malignancies of the Dose Proportionality of Subcutaneous Azacitidine and Its Pharmacokinetics in Patients with Severe Renal Impairment by Laille, Eric, Goel, Sanjay, Mita, Alain C., Gabrail, Nashat Y., Kelly, Kevin, Liu, Liangang, Songer, Stephen, Beach, Charles L.

“…Study Objective To assess the dose proportionality of azacitidine pharmacokinetics (PK) after single subcutaneous (SC) doses of 25–100 mg/m2, and determine the…”
Get full text

Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher‐risk myelodysplastic syndromes by Seymour, John F., Bennett, John M., List, Alan F., Mufti, Ghulam J., Gore, Steven D., Fenaux, Pierre, Santini, Valeria, Hetzer, Joel, Songer, Stephen, Skikne, Barry S., Beach, Charles L.

“…Summary The efficacy and tolerance of azacitidine in higher‐risk myelodysplasia with hypocellular bone marrow (BM) are unknown. This post hoc AZA‐001 trial…”
Get full text

Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis by Smith, B Douglas, Beach, Charles L, Mahmoud, Dalia, Weber, Laura, Henk, Henry J

“…This study examined patient outcomes using real world data for acute myeloid leukemia (AML) patients initiating treatment. A retrospective, administrative…”
Get full text

Erratum to: Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis by Smith, B Douglas, Beach, Charles L, Mahmoud, Dalia, Weber, Laura, Henk, Henry J

Get full text

Dose-response evaluation of once-daily therapy with a new formulation of diltiazem for stable angina pectoris by Thadani, Udho, Glasser, Stephen, Bittar, Neville, Beach, Charles L.

“…Diltiazem hydrochloride in a once-daily capsule formulation (DCD) has recently been approved in the United States for the treatment of mild to moderate…”
Get full text

Correction: Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis by Smith, B, Beach, Charles, Mahmoud, Dalia, Weber, Laura, Henk, Henry

Get full text